InnovAge Holding Corp. (INNV) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Hold
Based on 8 analysts24.2% Above Target
INNV trades 24.2% above Wall Street's consensus target of $6.80.
Current Price$8.97
Average Target$6.80
Target
Current
Low$5.00
Median$8.00
High$8.00
Analyst Target Range
Forward P/E83.0x
(High Premium)
PEG Ratio—
Implied Growth+166.1%
(High Growth)
Analyst Spread44.1%
(Moderate)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes INNV achieves its forward estimates and maintains a stable P/E multiple of 83.0x. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
INNV Price Target Analysis
Updated June 22, 2026As of June 22, 2026, InnovAge Holding Corp. (INNV) has a Wall Street consensus price target of $6.80, based on estimates from 8 covering analysts. With the stock currently trading at $8.97, this represents a potential downside of -24.2%. The company has a market capitalization of $1.22B.
Analyst price targets range from a low of $5.00 to a high of $8.00, representing a 44% spread in expectations. The median target of $8.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Hold, with 0 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 2 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, INNV trades at a trailing P/E of -40.8x and forward P/E of 83.0x. Analysts expect EPS to grow +166.1% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+3.2%
Industry Consensus
Avg Forward P/E
51.6x
(High Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ALHCAlignment Healthcare, Inc. | $4.5B | $21.86 | $24.33 | +11.3% | Buy | 118.7x | 16 |
 OSCROscar Health, Inc. | $7.4B | $28.40 | $24.20 | -14.8% | Hold | 31.5x | 11 |
 ENSGThe Ensign Group, Inc. | $9.0B | $153.65 | $222.33 | +44.7% | Buy | 20.3x | 13 |
 CCRNCross Country Healthcare, Inc. | $426M | $13.17 | $12.50 | -5.1% | Hold | 142.4x | 14 |
 UNHUnitedHealth Group Incorporated | $363.9B | $400.96 | $425.81 | +6.2% | Buy | 21.8x | 52 |
 HUMHumana Inc. | $43.3B | $360.65 | $298.50 | -17.2% | Hold | 40.8x | 44 |
 CVSCVS Health Corporation | $125.4B | $98.32 | $103.64 | +5.4% | Buy | 13.3x | 41 |
 CNCCentene Corporation | $30.1B | $61.02 | $59.00 | -3.3% | Buy | 17.5x | 43 |
 MOHMolina Healthcare, Inc. | $10.2B | $195.37 | $175.55 | -10.1% | Buy | 38.0x | 38 |
 WELLWelltower Inc. | $144.8B | $206.65 | $237.80 | +15.1% | Buy | 71.3x | 34 |
INNV — Frequently Asked Questions
Quick answers to the most common questions about buying INNV stock.
What is the INNV stock price target for 2026?
INNV's consensus price target is $6.8, -24.2% below the current price of $8.97. The 8 analysts tracking INNV see downside risk at present valuations.
Is INNV a buy, sell, or hold?
INNV has a consensus rating of "Hold" based on 8 Wall Street analysts. The rating breakdown is leaning bearish, with 2 Sell/Strong Sell ratings. The consensus 12-month price target of $6.8 implies -24.2% downside from current levels.
Is INNV stock overvalued or undervalued?
At a forward P/E of 82.9787x, INNV trades at a premium valuation. The consensus price target of $6.8 (-24.2% downside) suggests analysts may view current valuations as stretched.
How high can INNV stock go?
The most bullish Wall Street analyst has a price target of $8 for INNV, while the most conservative target is $5. The consensus of $6.8 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover INNV stock?
INNV is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 6 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the INNV stock forecast?
The 12-month INNV stock forecast based on 8 Wall Street analysts shows a consensus price target of $6.8, with estimates ranging from $5 (bear case) to $8 (bull case). The median consensus rating is "Hold".
What is INNV's forward P/E ratio?
INNV trades at a forward P/E ratio of 83.0x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy INNV stock?
Analysts are cautious on INNV, with 2 Sell ratings and a price target of $6.8 (-24.2% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do INNV price targets vary so much?
INNV analyst price targets range from $5 to $8, a 44% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $6.8 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare